Q4

Mountain Province Diamonds Announces Revised Details for Q4 and Full-Year 2023 Earnings Release and Conference Call

Retrieved on: 
Monday, March 25, 2024
Webcast, TSX, OTC, Q4

TORONTO, March 25, 2024 /PRNewswire/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) (OTC: MPVD) today announces revised details for its fourth quarter and full-year 2023 earnings release and conference call.

Key Points: 
  • TORONTO, March 25, 2024 /PRNewswire/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) (OTC: MPVD) today announces revised details for its fourth quarter and full-year 2023 earnings release and conference call.
  • The delay in the issuance of fourth quarter and year-end 2023 results is due to the financial audit process not being completed by the planned date.
  • Prior to the conference call, the Company will release Q4 and full-year 2023 financial results on April 1st, 2024 after-market, in line with its statutory reporting deadline.
  • The Company will now host its fourth quarter and full-year 2023 conference call on Tuesday April 2nd, 2024 at 11:00am ET.

Mountain Province Diamonds Announces Revised Details for Q4 and Full-Year 2023 Earnings Release and Conference Call

Retrieved on: 
Monday, March 25, 2024
Webcast, TSX, OTC, Q4

TORONTO, March 25, 2024 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) (OTC: MPVD) today announces revised details for its fourth quarter and full-year 2023 earnings release and conference call. The delay in the issuance of fourth quarter and year-end 2023 results is due to the financial audit process not being completed by the planned date.

Key Points: 
  • TORONTO, March 25, 2024 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) (OTC: MPVD) today announces revised details for its fourth quarter and full-year 2023 earnings release and conference call.
  • The delay in the issuance of fourth quarter and year-end 2023 results is due to the financial audit process not being completed by the planned date.
  • Prior to the conference call, the Company will release Q4 and full-year 2023 financial results on April 1st, 2024 after-market, in line with its statutory reporting deadline.
  • The Company will now host its fourth quarter and full-year 2023 conference call on Tuesday April 2nd, 2024 at 11:00am ET.

MGI – Media and Games Invest SE Invites Investors to the Presentation of its Year End Report Q4 2023 on February 29, 2024, at 13:00 CET

Retrieved on: 
Wednesday, March 13, 2024
Remco, CFO, Q4, Report, MGI, Cryptocurrency

MGI – Media and Games Invest SE Invites Investors to the Presentation of its Year End Report Q4 2023 on February 29, 2024, at 13:00 CET

Key Points: 
  • MGI – Media and Games Invest SE Invites Investors to the Presentation of its Year End Report Q4 2023 on February 29, 2024, at 13:00 CET
    February 26, 2024: MGI – Media and Games Invest SE (“MGI” or the “Company”, ISIN: SE0018538068; Ticker M8G; Nasdaq First North Premier Growth Market and Scale Segment Frankfurt Stock Exchange) will publish its Year End Report Q4 2023 on 29 February, 2024 at 08:00 CET and invites investors to participate in the presentation of the Q4 results by Remco Westermann (CEO) and Paul Echt (CFO) on Thursday, 29 February 2024 at 13:00 CET.
  • The presentation will be held in English and will also be available on-demand on the Company’s website www.mgi-se.com.

ARCHER-DANIELS-MIDLAND COMPANY (NYSE: ADM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Archer-Daniels-Midland Company

Retrieved on: 
Monday, March 11, 2024
Court, Nutrition, News, Advertising, Growth, Sale, Complaint, District court, Q4, ADM, FY, ADM (company)

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Archer-Daniels-Midland Company (NYSE: ADM)?
  • Throughout the Class Period, Defendants made misleading statements about the Nutrition segment as a future profit-driver for the Company.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mobileye, BioVie, ADM, and B. Riley and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, March 10, 2024
Complaint, OSI, FRG, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C, Audit

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.
  • As alleged, Defendants’ accounting practices for the segment misrepresented its true financial results and prospects, including its operating profits (“OP”).
  • For more information on the B. Riley class action go to: https://bespc.com/cases/RILY

ARCHER-DANIELS-MIDLAND COMPANY (NYSE: ADM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Archer-Daniels-Midland Company

Retrieved on: 
Thursday, March 7, 2024
Court, Nutrition, News, Advertising, Growth, Sale, Complaint, District court, Q4, ADM, FY, ADM (company)

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Archer-Daniels-Midland Company (NYSE: ADM)?
  • Throughout the Class Period, Defendants made misleading statements about the Nutrition segment as a future profit-driver for the Company.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

NewtekOne, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
BDC, Acquisition, NEWT, NewTek, Friction, Forecasting, PLP, Net income, Adjustment, Human, Conference, Q4, BOCA, GAAP, Webcast, EPS, Asset, National bank, Bank statement, SBA, RIC, Environment, Clothing

BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (Nasdaq: NEWT), announced today its financial and operating results for the three and twelve months ended December 31, 2023.

Key Points: 
  • Total assets were $1.4 billion at December 31, 2023, which remained relatively consistent to the balance at September 30, 2023.
  • Total borrowings were $644.1 million at December 31, 2023; a decrease of 0.7% from $648.7 million at September 30, 2023.
  • Please visit our website and review our Fourth Quarter and Full Year 2023 Presentation.”
    A conference call to discuss the fourth quarter and full year 2023 financial results will be hosted by Barry Sloane, President, Chairman and Chief Executive Officer, M. Scott Price, Chief Financial Officer, and Nick Leger, Chief Accounting Officer, tomorrow, Wednesday, March 6, 2024, 8:30 a.m.
  • Please note, to attend the conference call or webcast, participants should register online at NewtekOne, Inc. Q4 and Full Year 2023 Financial Results Conference Call .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 6, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

ADM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Archer-Daniels-Midland Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, March 6, 2024
Court, Person, News, Growth, Complaint, Q4, ADM, FY, ADM (company), Defendant

As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.

Key Points: 
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As alleged, Defendants’ accounting practices for the segment misrepresented its true financial results and prospects, including its operating profits (“OP”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM